Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2007 4
2008 6
2009 8
2010 15
2011 13
2012 15
2013 20
2014 12
2015 9
2016 13
2017 11
2018 15
2019 17
2020 10
2021 13
2022 6
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. N Engl J Med. 2018. PMID: 30403574 Free article. Clinical Trial.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Ray KK, et al. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Lancet Diabetes Endocrinol. 2019. PMID: 31272931 Free article. Clinical Trial.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
Pharmacological interactions: the next frontier?
Bonello L, Paganelli F, Laine M. Bonello L, et al. Among authors: paganelli f. JACC Cardiovasc Interv. 2013 Feb;6(2):180-1. doi: 10.1016/j.jcin.2012.12.008. JACC Cardiovasc Interv. 2013. PMID: 23428010 Free article. No abstract available.
Wearable cardioverter defibrillator: Bridge or alternative to implantation?
Barraud J, Cautela J, Orabona M, Pinto J, Missenard O, Laine M, Thuny F, Paganelli F, Bonello L, Peyrol M. Barraud J, et al. Among authors: paganelli f. World J Cardiol. 2017 Jun 26;9(6):531-538. doi: 10.4330/wjc.v9.i6.531. World J Cardiol. 2017. PMID: 28706588 Free PMC article. Review.
High on treatment platelet reactivity.
Ait-Mokhtar O, Bonello L, Benamara S, Paganelli F. Ait-Mokhtar O, et al. Among authors: paganelli f. Heart Lung Circ. 2012 Jan;21(1):12-21. doi: 10.1016/j.hlc.2011.08.069. Epub 2011 Oct 13. Heart Lung Circ. 2012. PMID: 22000771 Review.
Pleiotropic effects of ticagrelor: Myth or reality?
Aït Mokhtar O, Gaubert M, Laine M, Bonello L, Guieu R, Cautela J, Peyrol M, Barraud J, Thuny F, Dignat-Georges F, Sabatier F, Fromonot J, Rossi P, Paganelli F. Aït Mokhtar O, et al. Among authors: paganelli f. Arch Cardiovasc Dis. 2016 Aug-Sep;109(8-9):445-8. doi: 10.1016/j.acvd.2016.04.001. Epub 2016 Jun 21. Arch Cardiovasc Dis. 2016. PMID: 27342807 Free article. Review. No abstract available.
Diagnostic Value of the International Society of Cardio-Oncology Definition for Suspected Immune Checkpoint Inhibitor-Associated Myocarditis.
Deharo F, Thuny F, Cadour F, Resseguier N, Meilhac A, Gaubert M, Dolladille C, Paganelli F, Alexandre J, Cautela J. Deharo F, et al. Among authors: paganelli f. J Am Heart Assoc. 2023 Apr 18;12(8):e029211. doi: 10.1161/JAHA.122.029211. Epub 2023 Apr 12. J Am Heart Assoc. 2023. PMID: 37042287 Free PMC article. No abstract available.
Antithrombotic strategies in elderly patients with acute coronary syndrome.
Dillinger JG, Laine M, Bouajila S, Paganelli F, Henry P, Bonello L. Dillinger JG, et al. Among authors: paganelli f. Arch Cardiovasc Dis. 2021 Mar;114(3):232-245. doi: 10.1016/j.acvd.2020.12.002. Epub 2021 Feb 23. Arch Cardiovasc Dis. 2021. PMID: 33632631 Free article. Review.
154 results